

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
Leonard Frank X			9/1/2020		NovoCure Ltd [NVCR]		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Development Officer /				
(Street)			5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)		
MALVERN, PA 19355					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	59811	D	
Restricted Share Units	1465 (1)	D	
Restricted Share Units	733 (2)	D	
Restricted Share Units	5314 (3)	D	
Restricted Share Units	3001 (4)	D	
Restricted Share Units	5405 (5)	D	
Restricted Share Units	5904 (6)	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options to Buy Ordinary Shares	(7)	2/23/2025	Ordinary Shares	14784.0	\$14.37	D	
Options to Buy Ordinary Shares	(7)	2/24/2026	Ordinary Shares	15000.0	\$11.46	D	
Options to Buy Ordinary Shares	(8)	2/21/2027	Ordinary Shares	19500.0	\$7.15	D	
Options to Buy Ordinary Shares	(9)	2/26/2028	Ordinary Shares	32103.0	\$21.15	D	
Options to Buy Ordinary Shares	(10)	7/30/2028	Ordinary Shares	16148.0	\$34.0	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options to Buy Ordinary Shares	(11)	3/21/2029	Ordinary Shares	14595.0	\$47.04	D	
Options to Buy Ordinary Shares	(12)	7/30/2029	Ordinary Shares	7809.0	\$83.3	D	
Options to Buy Ordinary Shares	(13)	3/2/2030	Ordinary Shares	10422.0	\$69.37	D	
Options to Buy Ordinary Shares	(14)	8/31/2030	Ordinary Shares	11336.0	\$84.68	D	

Explanation of Responses:

- (1) Represents restricted share units that are scheduled to vest on February 27, 2021, subject to the reporting person's continued employment through such date.
- (2) Represents restricted share units that are scheduled to vest on July 31, 2021, subject to the reporting person's continued employment through such date.
- (3) Represents restricted share units that are scheduled to vest in equal installments on each of March 22, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (4) Represents restricted share units that are scheduled to vest in equal installments on each of July 30, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (5) Represents restricted share units that are scheduled to vest in equal installments on each of March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (6) Represents restricted share units that are scheduled to vest in equal installments on each of September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (7) Currently exercisable.
- (8) Options to buy 19,500 ordinary shares, 13,000 shares of which are currently exercisable and the remainder vest on February 22, 2021.
- (9) Options to buy 32,103 ordinary shares, 16,052 shares of which are currently exercisable and the remaining 16,061 shares of which will vest and become exercisable in equal installments on each of February 27, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (10) Options to buy 16,148 ordinary shares, 8,074 shares of which are currently exercisable and the remaining 8,074 shares of which will vest and become exercisable in equal installments on each of July 31, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (11) Options to buy 14,595 ordinary shares, 3,649 shares of which are currently exercisable and the remaining 10,946 shares will vest and become exercisable in equal installments on each of March 22, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (12) Options to buy 7,809 ordinary shares, 1,953 shares of which are currently exercisable and the remaining 5,856 shares of which will vest and become exercisable in equal installments on each of July 30, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (13) Options to buy 10,422 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
- (14) Options to buy 11,336 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Leonard Frank X C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN, PA 19355			Chief Development Officer	

Signatures

By: /s/ Steven Robbins, Attorney in Fact for Frank X. Leonard

9/10/2020

****Signature of Reporting Person**

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).